Youâre reading a free article with opinions that may differ from The Motley Foolâs Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.
RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partnerâs brokerage products, these are focused on the trading of readily releasable securities.
VIDEO: One Fool takes a closer look at GlaxoSmithKline plc (LON:GSK) and AstraZeneca plc (LON:AZN)
The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.
Youâre reading a free article with opinions that may differ from The Motley Foolâs Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.
RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partnerâs brokerage products, these are focused on the trading of readily releasable securities.
These two British drugs behemoths are similar businesses that both pay big dividends, and they’ve mostly tended to move in lockstep. However, in recent months GlaxoSmithKline (LSE: GSK) has sported a much higher — and hence more potentially more attractive — yield than AstraZeneca (LSE: AZN). So what’s up? Owain Bennallack investigates…
